Personalized medicine, pharmacogenomics (PGx) and the rise of companies such as 23andMe – offering individualized genetic testing – continue to gain momentum and change the landscape around genetic medicine. All of these trends and products are continuing to affect how a patient’s genetic makeup informs medication efficacy, the emergence of disease and their overall health.
Scott Lust, RPh and Cardinal Health senior consultant, clinical operations explained: “The variability of patient responses to drugs is observable, but it has been only recently that focused efforts on discovering the link between a patient’s genetic makeup and the influence on drug metabolism has been made. Pharmacogenomics is a big step toward advancing personalized medicine.”
We expect to see the trend continue of additional companies emerging in the genetics niche. Startups such as LunaDNA recently launched a sequencing platform to patients for their data and Nebula Genomics offers a more in-depth analysis and will sequence entire patient genomes.
“At a population level, companies like these will drive more links between genetics and long-term outcomes,” said David Taffany, PhD and Cardinal Health innovation solutions consultant. “Tracking, measuring and understanding outcomes is key. You must be able to look for the causal relationship between data and outcomes. Data-scientists, genetic counselors, trained pharmacists and other providers are essential to making genetic data actionable.”
This is obviously an area where change is happening quickly to help patients use their genetic data to make informed decisions.